NYSE:DPLO - Diplomat Pharmacy Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.11 -0.15 (-2.85 %)
(As of 05/24/2019 06:00 AM ET)
Previous Close$5.26
Today's Range$4.97 - $5.23
52-Week Range$4.99 - $28.74
Volume572,201 shs
Average Volume802,510 shs
Market Capitalization$381.77 million
P/E Ratio25.55
Dividend YieldN/A
Beta0.69
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.4435 per share
Book Value$6.13 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$381.77 million
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) issued its earnings results on Tuesday, May, 7th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.07 by $0.26. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The company's quarterly revenue was down 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy updated its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $-0.65--0.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.34. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $4.82 billion.Diplomat Pharmacy also updated its FY19 guidance to ($0.65-0.44) EPS.

What price target have analysts set for DPLO?

13 equities research analysts have issued 1 year price targets for Diplomat Pharmacy's stock. Their predictions range from $6.00 to $30.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $10.25 in the next year. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

Media stories about DPLO stock have been trending neutral on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Activision Blizzard (ATVI), XOMA (XOMA), CVS Health (CVS), Cannabis Sativa (CBDS), Karyopharm Therapeutics (KPTI), Netflix (NFLX) and Servicesource International (SREV).

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.43%), Dimensional Fund Advisors LP (3.02%), Northern Trust Corp (1.71%), Frontier Capital Management Co. LLC (1.46%), Cambridge Investment Research Advisors Inc. (1.08%) and FMR LLC (0.92%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which institutional investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., FMR LLC, JPMorgan Chase & Co., Cambridge Investment Research Advisors Inc., New York State Common Retirement Fund, BlackRock Inc., Frontier Capital Management Co. LLC and Northern Trust Corp. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

Which institutional investors are buying Diplomat Pharmacy stock?

DPLO stock was purchased by a variety of institutional investors in the last quarter, including Stephens Inc. AR, Morgan Stanley, Trexquant Investment LP, Dimensional Fund Advisors LP, Laurion Capital Management LP, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and Wells Fargo & Company MN. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $5.11.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $381.77 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  330 (Vote Underperform)
Total Votes:  637
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel